LakeShore Biopharma Co Long Term Debt

As of the most recent data (March 2025), YS shows a long-term debt of $24M. That compares with $100M in the prior-year period — down 76.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, YS's long-term debt is now $24M (was $100M) — a 76.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether LakeShore Biopharma Co is outperforming or lagging.

Tracking YS's long-term debt over time shows whether LakeShore Biopharma Co is scaling, shrinking, or reshaping that part of the business. The current reading is $24M That compares with $100M in the prior-year period — down 76.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has LakeShore Biopharma Co's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $24M) with ownership activity and broader fundamentals.